Report of Foreign Issuer (6-k)
September 08 2020 - 6:37AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of September 2020
Commission
File Number: 001-37643
KITOV
PHARMA LTD.
(Translation
of registrant’s name into English)
One
Azrieli Center, Round Tower, Tel Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On
September 4, 2020, Kitov Pharma Ltd. (the “Company”) received a notification letter from Nasdaq stating that
Nasdaq has determined that for ten consecutive business days (from August 21, 2020 through September 3, 2020), the closing bid
price of the Company’s American Depositary Shares (ADSs) has been at $1.00 per ADS or greater, and accordingly, the Company
has regained compliance with its minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing
Rule 5550(a)(2) and the matter is now closed.
Incorporation
by Reference
This
Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration
Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117
and 333-211477), the
Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s
Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s
Registration Statement on Form
F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195),
the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s
Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s
Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327), the Registrant’s
Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333- 238229), the Registrant’s
Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 28, 2020 (Registration file number 333-238481) and each of the
Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration
file numbers 333-239807
and 333-233793),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
September
8, 2020
|
KITOV
PHARMA LTD.
|
|
|
|
|
By:
|
/s/
Isaac Israel
|
|
|
Isaac
Israel
|
|
|
Chief
Executive Officer
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024